ALPL and prostate cancer: Serum bone alkaline phosphatase (B-ALP, gene ALPL) has long been understood to be elevated in men with prostate cancer and bone metastases and was originally described by Huggins and Hodges to transiently rise and then fall after orchiectomy and clinical response to androgen deprivation therapy[12].